Association of AMP-activated protein kinase with risk and progression of non-Hodgkin lymphoma.

ABSTRACT: Metabolic dysregulation has been identified as an "emerging hallmark" of cancer. The heterotrimeric AMP-activated protein kinase (AMPK) complex is a central regulator of the metabolic system and an important component of the mTOR pathway and the p53 axis, making it uniquely positioned to influence carcinogenesis through its canonical functions in the metabolic arena, as well as through more traditional mechanisms such as regulation of apoptosis and angiogenesis.We conducted a population-based genetic association study to examine the impact of mutations in AMPK subunit genes on risk of non-Hodgkin lymphoma (NHL). We also analyzed public microarray data to determine the expression of AMPK in NHL cells and to assess the influence of AMPK expression on overall survival in patients with NHL.We identified an AMPK subunit haplotype, which was significantly associated with NHL [OR, 5.44, 95% confidence interval (CI), 2.15-13.75] in women with no family history of cancer. Haplotypes in two subunits, PRKAA2 and PRKAG3, were nominally associated with the follicular and diffuse large B-cell lymphoma histologic subtypes, respectively, although these associations did not retain statistical significance after correction for multiple comparisons. Further, both of these subunits were differentially expressed (P < 0.05) in one or more lymphoma cell type, and higher expression of two versions of the AMPK-? subunit was significantly associated with increased 5-year survival among patients with NHL (P = 0.001 and P = 0.021).These results provide evidence for AMPK involvement in the pathogenesis and progression of NHL.These findings may lead to a novel area of research into NHL treatment and chemoprevention.

SUBMITTER: Hoffman AE 

PROVIDER: S-EPMC3631103 | biostudies-literature | 2013 Apr

REPOSITORIES: biostudies-literature